Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02706964 · ClinicalTrials.gov registry record · NA

Imaging the Patterns of Breast Cancer Early Metastases

A NA study of Breast Cancer, sponsored by University of Florida.

Completed
Registry status
NA
Development phase
13
Enrollment target
2
Study locations

NCT02706964 is a NA study of Breast Cancer that has completed, run by University of Florida. The registered enrollment target is 13 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02706964, a NA study of Breast Cancer, has completed, sponsored by University of Florida.

COMPLETED
Registry status
NA
Development phase
13 participants
Enrollment target
2
Study locations

Study Summary

Currently, once a distant breast metastasis has been diagnosed, 65% of patients will succumb to their cancer within 2 years, and 80% will succumb by 5 years. The current National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer do not recommend surveillance imaging for earlier detection of distant metastases, even for high-risk breast cancer patients. Whereas, the standard-of-care treatment of the small isolated (few in number) breast cancer metastases is to perform surgical resection or locally ablative radiation therapy, however, the follow-up of breast cancer patients (including those with a \>= 30% risk of developing metastases) is to wait for clinical symptoms to appear before using a dual positron emission tomography (PET) and diagnostic quality computed tomography (CT) PET/CT scan, magnetic resonance imaging (MRI), computed tomography (CT) or a bone scan to identify the site and extent of spread. Unfortunately, once metastases become symptomatic they are often too large and/or numerous to treat with curative intent. The current national care guidelines that advocate against intensive surveillance for distant metastases are based on two studies performed in Italy from 1985-1993 that concluded that the available imaging and treatment tools of the day did not prolong 5-year survival. Since then, however, there have been major improvements in imaging and treatment technology. To be treatable the metastases must be limited in number and limited in size, typically 6 or fewer metastases, each of size 5 centimeter or less. This state of metastatic presentation is called oligometastases. Numerous pilot studies have achieved dramatically improved overall and disease-free survival when oligometastases are treated using a combined systemic plus locally-ablative therapy of each oligometastasis. A scientific concern with the aforementioned research studies involving ablation of isolated oligometastases, was that they were not carried out w

Conditions Studied

Interventions

  • DEVICE Magnetic resonance imaging
  • DEVICE Positron emission tomography/x-ray computed tomography
  • DEVICE x-ray computed tomography (CT)

Study Locations (2)

Florida

  • Department of Radiation Oncology Davis Cancer Pavilion - Gainesville
  • University of Miami, Sylvester Comprehensive Cancer Center - Miami

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2016-04
Est. Completion 2022-02-16
Phase NA

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT02706964

The ClinicalTrials.gov registry entry for NCT02706964 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Magnetic resonance imaging is the first listed.

NCT02706964 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT02706964 about?

NCT02706964 is a clinical study titled "Imaging the Patterns of Breast Cancer Early Metastases". Currently, once a distant breast metastasis has been diagnosed, 65% of patients will succumb to their cancer within 2 years, and 80% will succumb by 5 years. The current National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer do not recommend surveillance imaging ...

What is the current status of trial NCT02706964?

This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2016-04. Estimated completion is 2022-02-16.

What conditions does trial NCT02706964 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02706964?

The interventions under investigation include: Magnetic resonance imaging (DEVICE), Positron emission tomography/x-ray computed tomography (DEVICE), x-ray computed tomography (CT) (DEVICE).

Who is sponsoring clinical trial NCT02706964?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02706964 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.